Structure-Based Druggability Assessment of the Mammalian Structural Proteome with Inclusion of Light Protein Flexibility

Advances reported over the last few years and the increasing availability of protein crystal structure data have greatly improved structure-based druggability approaches. However, in practice, nearly all druggability estimation methods are applied to protein crystal structures as rigid proteins, with protein flexibility often not directly addressed. The inclusion of protein flexibility is important in correctly identifying the druggability of pockets that would be missed by methods based solely on the rigid crystal structure. These include cryptic pockets and flexible pockets often found at protein-protein interaction interfaces. Here, we apply an approach that uses protein modeling in concert with druggability estimation to account for light protein backbone movement and protein side-chain flexibility in protein binding sites. We assess the advantages and limitations of this approach on widely-used protein druggability sets. Applying the approach to all mammalian protein crystal structures in the PDB results in identification of 69 proteins with potential druggable cryptic pockets.

[1]  A. Whitty,et al.  Small-molecule inhibition of TNF-alpha. , 2005, Science.

[2]  Katrina W Lexa,et al.  Full protein flexibility is essential for proper hot-spot mapping. , 2011, Journal of the American Chemical Society.

[3]  Thomas A. Halgren,et al.  Identifying and Characterizing Binding Sites and Assessing Druggability , 2009, J. Chem. Inf. Model..

[4]  Ruben Abagyan,et al.  Pocketome: an encyclopedia of small-molecule binding sites in 4D , 2011, Nucleic Acids Res..

[5]  Dima Kozakov,et al.  FTFlex: accounting for binding site flexibility to improve fragment-based identification of druggable hot spots , 2013, Bioinform..

[6]  Laurie E. Grove,et al.  Structural conservation of druggable hot spots in protein–protein interfaces , 2011, Proceedings of the National Academy of Sciences.

[7]  Robert P. Sheridan,et al.  Drug-like Density: A Method of Quantifying the "Bindability" of a Protein Target Based on a Very Large Set of Pockets and Drug-like Ligands from the Protein Data Bank , 2010, J. Chem. Inf. Model..

[8]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[9]  Holger Wesche,et al.  Structure guided design of a series of sphingosine kinase (SphK) inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[10]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[11]  Friedrich Rippmann,et al.  TRAPP: A Tool for Analysis of Transient Binding Pockets in Proteins , 2013, J. Chem. Inf. Model..

[12]  M. Jacobson,et al.  Binding-Site Assessment by Virtual Fragment Screening , 2010, PloS one.

[13]  Jun Wang,et al.  Small-Molecule Inhibition of TNF-α , 2005, Science.

[14]  Guilhem Faure,et al.  InterEvol database: exploring the structure and evolution of protein complex interfaces , 2011, Nucleic Acids Res..

[15]  Christopher A. Lipinski,et al.  Capter 11 Filtering in Drug Discovery , 2005, Annual Reports in Computational Chemistry.

[16]  J Andrew McCammon,et al.  A molecular dynamics ensemble-based approach for the mapping of druggable binding sites. , 2012, Methods in molecular biology.

[17]  I. Bahar,et al.  Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules. , 2013, Journal of chemical theory and computation.

[18]  Scott P. Brown,et al.  Effects of Conformational Dynamics on Predicted Protein Druggability , 2006, ChemMedChem.

[19]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[20]  F. J. Luque,et al.  Binding site detection and druggability index from first principles. , 2009, Journal of medicinal chemistry.

[21]  Eric T. Kim,et al.  How does a drug molecule find its target binding site? , 2011, Journal of the American Chemical Society.

[22]  Mishal N. Patel,et al.  Objective assessment of cancer genes for drug discovery , 2012, Nature Reviews Drug Discovery.

[23]  Alan C. Cheng,et al.  Chapter 2 – Predicting Selectivity and Druggability in Drug Discovery , 2008 .

[24]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[25]  Eric B Fauman,et al.  Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics. , 2011, Current opinion in chemical biology.

[26]  W. Sherman,et al.  Thermodynamic analysis of water molecules at the surface of proteins and applications to binding site prediction and characterization , 2011, Proteins.

[27]  Alan C. Cheng,et al.  Structure-Based Identification of Small Molecule Binding Sites Using a Free Energy Model , 2006, J. Chem. Inf. Model..

[28]  V. Helms,et al.  Transient pockets on protein surfaces involved in protein-protein interaction. , 2007, Journal of medicinal chemistry.

[29]  Dima Kozakov,et al.  FTMAP: extended protein mapping with user-selected probe molecules , 2012, Nucleic Acids Res..

[30]  Philippe Roche,et al.  2P2Idb: a structural database dedicated to orthosteric modulation of protein–protein interactions , 2012, Nucleic Acids Res..

[31]  Ricardo Macarron,et al.  Critical review of the role of HTS in drug discovery. , 2006, Drug discovery today.

[32]  Daniel R. Caffrey,et al.  Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.

[33]  Ming Yi,et al.  bioDBnet: the biological database network , 2009, Bioinform..

[34]  David K. Johnson,et al.  Druggable Protein Interaction Sites Are More Predisposed to Surface Pocket Formation than the Rest of the Protein Surface , 2013, PLoS Comput. Biol..

[35]  Andrew C. R. Martin Databases and ontologies Mapping PDB chains to UniProtKB entries , 2005 .

[36]  F. Javier Luque,et al.  MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories , 2011, Bioinform..

[37]  Erinna F. Lee,et al.  Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family , 2007, Cell Death and Differentiation.

[38]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.